Introduction
Inhaled steroids are the most effective therapy for asthma currently available, and have now become first-line therapy for chronic asthma internationally ( 1 ) . Although it is clear that their advantage in asthma treatment lies in their excellent topical anti-inflammatory effect with minimal systemic effects, several unwanted systemic side effects may occur, especially when high doses of inhaled steroids are used (2) . Among these, suppression of the hypothalamo-pituitary-adrenal (HPA) axis is important not only as a serious systemic side effect itself but also as a marker of other systemic effects (3) . Although the influence of high dose inhaled steroids on HPA function has been extensively studied, especially in Europe (4-9), there has been limited information on such an influence in Inhaled Steroids and Adrenal Function Furthermore, some studies included asthmatics who had been taking concomitant systemic steroids. Under such circumstances, it may be difficult to discuss the influence of inhaled steroids separately from that of systemic steroids. Wepreviously conducted a cross-sectional study of HPA axis function in Japanese asthmatics which revealed no suppression in patients inhaling less than 800 |ag/day of beclomethasone dipropionate (BDP) (1 1) . In the present study, a change in HPAfunction in the course of time was examined using serial short tetracosactrin tests in Japanese asthmatics treated with high dose inhaled steroids (800 Jig/day or more of BDP) alone.
Materials and Method
In our previous study, 94 patients were given a short tetracosactrin test (STT). Of these, 1 1 were selected to undergo a 2nd test. These patients, who therefore formed the basis of our analysis in the present study, (a) inhaled 800 |ig/day or more of BDP and (b) received no systemic steroids (neither short courses nor regular use) during the period between their 2 STTs.
Patients were requested to cometo the outpatient clinic of Kobe City General Hospital between 9:30 and ll:00 AM. Following venous sampling for measurement of serum cortisol (basal cortisol), a STT was performed using a 0.25 mg i.v. dose of tetracosactid (cortrocin). Venous sampling was repeated after 30 and 60 minutes, and the higher cortisol level of the 2 samplings was defined as the maximumcortisol. HPAsuppression was indicated when maximumcortisol failed to reach 18 |Lig/dl. The 2nd STT was intended to be performed approximately one year after the 1st STT although in the end, the interval between the 2 tests was actually 392±28 days (mean+SD).
Statistical analysis was performed using STATVIEW4.0. Changesin serum cortisol in the course of time were compared using Wilcoxon signed-rank test. Comparisons of several cortisol values between patients with and without previous systemic steroids were madeusing unpaired t test.
Results
Selected characteristics of the study subjects are shownin Table 1 . Themeanage was 53 years old. There were4 males and 7 females. Doses ofBDP were between 800 and 1,600 |ng/day, and the meanduration of BDPinhalation was 1,468 days. Although no patients received any systemic steroids between their 2 STTs, 3 patients (cases 9, 10 and ll in Table 1 ) had received short courses of oral steroids before their 1st test. These 3 patients had also received regular systemic steroids until about 66, 36 and 59 months, respectively, before their 1st STTs. In these patients, their 1st STTs were performed at least 4 weeksafter the completion of the final course of their short courses of oral steroids. The remaining 8 patients had never received regular, nor short courses of oral steroids. Serum cortisol before the administration of basal cortisol, maximumcortisol, and the rise in cortisol in response to ACTH in the 2 serial STTs are shown in Table 2 . Mean±SDof basal cortisol, maximumcortisol and the rise in cortisol was 7.8±2.6 jig/dl, 20.5±6.4 jig/dl and 12,7+5.9 jLtg/dl, respectively for the 1st test, and 8.9+2.5 jig/dl, 23.6±4.8 jag/dl and 14.7±5.6 jug/dl, respectively for the 2nd test. They were all within their normal ranges, and none of the changes in the 2 tests was statistically significant. Mean levels of maximumcortisol in the 1st STT were significantly lower in patients with previous systemic steroids than in patients without them ( 14.4±4.4 vs 22.8+5.5 jag/ dl, p<0.05). They became identical in the 2nd STT (23.6±6.3 vs Brown et al (13) reported they are equally sensitive and, indeed, they are moresensitive than a single measurement of 9:00 AMplasma cortisol. Short tetracosactrin tests were used in the present study due to both the ease of use in an outpatient setting and their sensitivity. Furthermore, there seems to be no consensus on diagnosing HPAdysfunctions in STT. Some use maximumcortisol (8) or the rise in cortisol (12) alone, others (4, 6, 7) use the combination of these. In the present study, all STTswere performed between 9:30 AMand ll:00 AM,but not at exactly the same time. Werealize that basal cortisol value may be affected by the circadian rhythm of plasma cortisol, and the rise in cortisol may also be affected because it was calculated using basal cortisol. Because of this, we diagnosed HPAdysfunction only by the maximumcortisol level in the present study. As a cut-off value to diagnose an abnormalresponse, manyprevious studies used either 500 nM (approximately 17.3 jag/dl) or 18 jig/dl; we employed the latter cut-off value.
Influence of systemic steroids Asthmatics whoneed high dose inhaled steroids to control their symptoms generally have severe asthma. Naturally, many of themsometimesneed either short courses or regular use of systemic steroids. A review of the literature revealed that some of the reports which deal with inhaled steroids and HPA function analyzed asthmatics both with and without systemic steroids concomitantly. In this situation, it may be difficult to discuss the influence of inhaled steroids separately from that of systemic steroids.
In the present study, we selected ll asthmatics whohad never used any systemic steroids between their 2 STTs, but 3 of them had received such drugs before their 1st STT. In other words, these patients had recently succeeded in withdrawing from systemic steroids with the use of inhaled steroids. Although the results of the 1 st STTs in all 3 patients revealed HPA suppression, they experienced dramatic improvements in HPA 364 Internal Medicine Vol.-35, No. 5 (May 1996) function in the course of time in their 2nd STTs. The results of the 1st STTs in these 3 patients might have been influenced largely by their previous systemic steroids, because the influence of systemic steroids seemsto persist several years after their completion (14).
Safety of high dose inhaledsteroids in Japanese asthmatics Of 8 patients who had never taken systemic steroids, 4 had a reduced maximum cortisol level, while the other 4 had an improved maximumcortisol level in their 2nd STTs. The doses ofBDP were 800 jiig/day in 3 of the 4 patients who experienced improvement, and 1,200 Jig/day for 3 of the 4 patients who showeddeterioration. Furthermore, in one patient whonewly developed an abnormal response to ACTHin her 2nd test, BDP was increased from 800 |Lig/day to 1,200 jag/day between the two tests. These results suggest that a threshold dose resulting in HPAsuppression in Japanese asthmatics exists between 800 and 1,200 |ig/day. In other words, an international consensus (2) which suggests that doses up to 1,000 Jig/day are safe in terms of systemic side effects, could also be applied to Japanese asthmatic s.
However, one patient whose BDPdose was increased from 800 Jig/day to 1 ,600 |Lig/day, showed an improvement of HPA function in his 2nd test. This suggests that an increased dose of BDPmay not consistently be associated with HPAdysfunction in certain subjects. A review of the literature also revealed that the relationship between doses and HPAfunction is not always clear.
Smith and Hodson (4) reported that maximumcortisol in
STTs was similar in asthmatics inhaling both 1,000 and 1,500 (ig/day, but significantly lower in asthmatics inhaling 2,000 | ig/ day ofBDP. Boe et al (5) prospectively compared efficacy and HPAsuppression with 1.6 mg ofBDPand 2.0 mg offluticasone propionate, and reported that HPAsuppression developed only when 2.0 mgoffluticasone was used. On the other hand, Brown et al (6) examined 78 asthmatics who were inhaling 1,200-2,650 Jig/day ofBDP or budesonide, and reported that there was no significant correlation between doses of BDPand HPAaxis function. Altman et al (7) performed STTs in 143 asthmatics who were inhaling 800, 1,200, 1 ,600 Jig/day of triamcinolone acetonide. They repeated STTs before and 2 weeks, 1 month, 3 monthsand 6 monthsafter treatment. There wasno difference in the incidence of HPAsuppression either according to dose or time. Three patients were diagnosed as having HPAsuppression. Two of them were inhaling 1 ,600 Jig/day, but the other was inhaling 800 | ig/day. Furthermore, this latter patient developed HPAsuppression only 2 weeks after starting treatment with inhaled steroids. It was not clear whythe patient with the lowest dose developed HPAsuppression so early, while the majority of patients with the highest dose revealed no suppression throughout the 6 months of the study period, although interindividual differences in sensitivity to exogenous steroids might play an import role. Results of a prospective dose escalation study of inhaled steroids also suggest that there is wide interindividual variation in doses of BDPresulting in HPAsuppression (8).
In consideration of this wide inter-individual variation, there may likewise be racial differences in sensitivity to exogenous steroids. Recently, Tornatore et al (10) reported that there was a difference in methylprednisolone clearance between black and white renal transplant recipients. In this context, we reanalyzed some of the previous reports. In a dose range of inhaled steroids between 800 and 1 ,200 Jig/day without the use of concurrent systemic steroids, Smith and Hodson (4) reported 1 outof34 and Altman et al (7) reported 1 outof78 patients with HPAsuppression. Because these studies used different drugs and there was also a difference in the criteria for HPAsuppression, they are not directly comparable with the results of the present study. But if wecompareour results with the combined total of these 2 previous reports, the incidence ofHPAsuppression with a dose of inhaled steroids between 800-1 ,200 Jig/day was 1 out of7 (14.3%) against 2 out of 112 (1.8%). Although the results of this comparison are not conclusive due to the very small sample size of the present study, they suggest that Japanese asthmatics could be more sensitive to this dose range of inhaled steroids than the European population.
All drugs should be evaluated in terms of the balance between their efficacy and their safety ( 1 5) . The fact that inhaled steroids have been extensively used during the past 20 years and are still recognized as the first line treatment for persistent asthma, suggests that these drugs do not have serious side effects which outweigh their clinical efficacy. But one should recognize the wide inter-individual variation in sensitivity to exogenous steroids. If the same dose of inhaled steroids is used in different patients, there may be a difference both in their efficacy and their safety, and as a consequence, in the balance between the two. Thus, when doses of 800 jag/day or more of BDPare used, screening for HPAfunction should routinely be performed. And whena decision needs to be madeas to whether the doses of BDPshould be increased or other drugs should be added, careful attention should be paid, case by case, for the balance between efficacy and safety of these different strategies.
Fromthe results of our study, wehave drawn the following conclusions: 1) The international consensus on the safety of prolonged treatment with high dose inhaled steroids is generally applicable to Japanese asthmatics, and 2) In the introduction to a treatment with high dose inhaled steroids, careful attention shuld be paid to the wide inter-individual variation in sensitivity to exogenous steroids.
